Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT
NCT ID: NCT00647205
Last Updated: 2011-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
240 participants
INTERVENTIONAL
2008-01-31
2010-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis
NCT01622140
Medical and Economical Impact of IGRAs Diagnosis of Latent Tuberculosis in HIV-infected Patients
NCT00805272
QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.
NCT01223534
Tuberculosis (TB) Screening for the Diagnosis of Latent TB in Immunocompromised Populations
NCT00134342
Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing in Patients With Chronic Liver Disease
NCT00402402
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
HIV infected antiretroviral naïve patients originated from low TB prevalence countries without any active TB with CD4 cell count \> 350/mm3
QuantiFERON TB Gold In-Tube
T-SPOT.TB®
2
HIV infected antiretroviral naïve patients originated from low TB prevalence countries without any active T with CD4 \< 350/mm3)
QuantiFERON TB Gold In-Tube
T-SPOT.TB®
3
HIV infected antiretroviral naïve patients originated from high TB prevalence countries without any active TB with CD4 \< 350/mm3)
QuantiFERON TB Gold In-Tube
T-SPOT.TB®
4
HIV infected antiretroviral naïve patients originated from high TB prevalence countries without any active TB with CD4 \> 350/mm3)
QuantiFERON TB Gold In-Tube
T-SPOT.TB®
5
HIV infected patients with active TB
QuantiFERON TB Gold In-Tube
T-SPOT.TB®
6
HIV negative patients with active TB
QuantiFERON TB Gold In-Tube
T-SPOT.TB®
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
QuantiFERON TB Gold In-Tube
T-SPOT.TB®
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* to be adult
* not to be pregnant
* to have a clinical examination and a medical questionnaire
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
French National Agency for Research on AIDS and Viral Hepatitis
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
ANRS
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniel Bonnet, MD
Role: PRINCIPAL_INVESTIGATOR
AP-HP Paris
France Mentre, PHD
Role: STUDY_DIRECTOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service des Maladies Infectieuses B Hopital Bichat
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANRS EP 40 QUANTI SPOT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.